risk reward amerisourcebergen corp abc
reason chang
updat pt account gener environ stabil methodolog
follow upgrad logic earlier week
 distribut unit state america
unless otherwis note metric base modelwar
base consensu methodolog
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
market leader specialti balanc risk-reward
wacc addit assum global opioid litig settlement
estim respons
second largest
drug wholesal us largest
specialti distributor posit benet
grow specialti pipelin
among distributor
highest revenu exposur higher-growth
higher-margin specialti
opioid liabil continu
distribut agreement
walgreen largest custom provid
compani long term revenu
visibl sourc benet
greater scrutini brand inat
gener deation limit new product
introduct like continu weigh
growth prole forseeabl futur
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
feb gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
view descript risk reward theme
ebitda excl opioid
assum brand inat goe hsd
gener inat lsd global opioid
liabil lower sell-sid discount
custom higher top-line growth
gross margin specialti
impli multipl modestli
maximum forward ev/ebitda
multipl past year
ebitda excl opioid
assum brand inat remain lsd-
msd gener deation lsd global
opioid liabil
impli multipl modestli
averag forward ev/ebitda multipl
period distributor
benet gener inat
ebitda excl opioid
assum brand inat goe zero
opioid liabil higher sell side
discount custom lower top-line
growth gross margin specialti
impli multipl in-lin averag
forward ev/ebitda multipl
drug price increas particularli januari
gener manufactur commentari gener
news ow opioid litig settlement
increas brand inat
acceler growth specialti drug
distribut servic
signic slowdown brand inat
deterior gener price deation
continu price pressur margin eros
increas opioid legal settlement payment
view explan region hierarchi
research highest favor quintil
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
